Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz Pharmaceuticals's Total Liabilities for the quarter that ended in Jun. 2026 was R$32,175 Mil.
Jazz Pharmaceuticals's quarterly Total Liabilities
declined
from Dec. 2025 (R$40,048.96 Mil) to Mar. 2026 (R$38,318.85 Mil) and
declined
from Mar. 2026 (R$38,318.85 Mil) to Jun. 2026 (R$32,175.25 Mil).
Jazz Pharmaceuticals's annual Total Liabilities
increased
from Dec. 2023 (R$37,514.64 Mil) to Dec. 2024 (R$48,310.78 Mil) but then
declined
from Dec. 2024 (R$48,310.78 Mil) to Dec. 2025 (R$40,048.96 Mil).
Jazz Pharmaceuticals Total Liabilities Related Terms
Jazz Pharmaceuticals Total Liabilities Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Jazz Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of R$32,175 Mil mean?
Jazz Pharmaceuticals (BSP:J2AZ34) has a Total Liabilities of R$32,175 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Total Liabilities too high?
Jazz Pharmaceuticals' current Total Liabilities is R$32,175 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Total Liabilities compare to BBIO and ASND?
Jazz Pharmaceuticals' Total Liabilities of R$32,175 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Total Liabilities is R$32,175 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (BSP:J2AZ34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$51.81, compared to a current price of R$87.12 — trading 68.2% above its estimated fair value. The current Total Liabilities is R$32,175 Mil. Jazz Pharmaceuticals' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Jazz Pharmaceuticals (BSP:J2AZ34), the current Total Liabilities is R$32,175 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (BSP:J2AZ34) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of R$87.12 is trading 68.2% above its estimated GF Value™ of R$51.81.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BSP:J2AZ34:
Total Liabilities: R$32,175 Mil
GF Value™: R$51.81 vs. price of R$87.12 (68.2% above fair value)
No single metric tells the full story. See the BSP:J2AZ34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
44GF Score
Get the complete analysis for BSP:J2AZ34
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:J2AZ34 has been successfully added to your 
